1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Cytoskeleton
  3. PAK

PAK

p21 activated kinases

PAKs (p21-activated kinases) are a family of six serine/threonine kinases that act as key effectors of RHO family GTPases in mammalian cells. PAKs are subdivided into two groups: group I (PAK1, PAK2, and PAK3) and group II (PAK4, PAK5, and PAK6), based on their domain architecture and regulation. Group I PAKs are activated by GTPases such as Cdc42, Rac, TC10, CHP, and Wrch-1, as well as in a GTPase-independent manner. Group II PAKs are generally not activated by Cdc42/Rac binding. PAK plays important roles in cytoskeletal organization, cellular morphogenesis, and survival, and members of this family have been implicated in many diseases including cancer, infectious diseases, and neurological disorders.

PAKs participate in various signaling networks. PAKs activate the MAPK pathway by phosphorylating Raf1 in addition to NF-κB. PAKs also phosphorylate a number of regulators of the cytoskeleton such as MLCK, LIMK, filamin A, ILK, merlin, and Arpc1b. In addition, PAKs regulate survival and apoptotic pathways through phosphorylation of its effectors such as DLC1 and BimL. On translocation to the nucleus, PAKs directly affect gene transcription. Several transcription factors and transcriptional co-regulators such as FKHR, SHARP, CTBP1 and SNAI1 are substrates to PAK1. PAKs also regulate cell cycle progression through phosphorylation of histone H3, Aurora A and PlK1.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS09989
    PAK2 Rat Pre-designed siRNA Set A
    Inhibitor

    PAK2 Rat Pre-designed siRNA Set A contains three designed siRNAs for PAK2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PAK2 Rat Pre-designed siRNA Set A
  • HY-155179
    ZMF-23
    Inhibitor
    ZMF-23 is a PAK1/HDAC6 dual inhibitor. ZMF-23 inhibits PAK1 and HDAC6 regulated aerobic glycolysis and migration. ZMF-23 induces TNF-α-regulated necroptosis, and further enhances apoptosis. ZMF-23 inhibits the Warburg effect and cell migration. ZMF-23 can be used for research of triple-negative breast cancer (TNBC).
    ZMF-23
  • HY-RS09998
    Pak5 Rat Pre-designed siRNA Set A
    Inhibitor

    Pak5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pak5 Rat Pre-designed siRNA Set A
  • HY-RS10000
    Pak6 Mouse Pre-designed siRNA Set A
    Inhibitor

    Pak6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pak6 Mouse Pre-designed siRNA Set A
  • HY-15027S2
    5-Aminosalicylic acid-13C6
    5-Aminosalicylic acid-13C6 is the 13C labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
    5-Aminosalicylic acid-<sup>13</sup>C<sub>6</sub>
  • HY-RS09990
    PAK3 Human Pre-designed siRNA Set A
    Inhibitor

    PAK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PAK3 Human Pre-designed siRNA Set A
  • HY-13007A
    PF-3758309 hydrochloride
    Inhibitor
    PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation.
    PF-3758309 hydrochloride
  • HY-159897
    PAK4-IN-5
    Inhibitor
    PAK4-IN-5 (Compound 12i) is a PAK4 inhibitor (IC50: 7.68 nM for PAK4, 1872.01 nM for PAK1). PAK4-IN-5 binds to PAK4 stably via multiple interactions. PAK4-IN-5 inhibits the proliferation and the migratory potential of MDA-MB-231 cells by inhibiting the phosphorylation of PAK4 and LIMK1. PAK4-IN-5 arrests cell cycle in the G0/G1 phase, induces apoptosis and ROS production. LD50: >500 mg/kg for mice (p.o.).
    PAK4-IN-5
  • HY-RS09993
    PAK4 Human Pre-designed siRNA Set A
    Inhibitor

    PAK4 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PAK4 Human Pre-designed siRNA Set A
  • HY-RS09988
    Pak2 Mouse Pre-designed siRNA Set A
    Inhibitor

    Pak2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pak2 Mouse Pre-designed siRNA Set A
  • HY-13007B
    PF-3758309 dihydrochloride
    Inhibitor
    PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation.
    PF-3758309 dihydrochloride
  • HY-174247
    CPS-021
    Degrader
    CPS-021 is a selective PAK4 PROTAC degrader with a DC50 of 50 nM. CPS-021 has potent antimigratory and invasive activity and significantly suppresses the invasion and metastasis of tumor cells in A549-luc lung metastasis mice model. Pink: PAK4 ligand (HY-174822); Blue: CRBN ligase ligand (HY-10984); Black: linker
    CPS-021
  • HY-116917
    G-9791
    Inhibitor
    G-9791, a poyridone side chain analogue, is a potent PAK inhibitor with Ki values of 0.95 nM and 2.0 nM for PAK1 and PAK2, respectively.
    G-9791
  • HY-110085
    2,2′-Dihydroxy-6,6′-dinaphthyl disulfide
    Inhibitor 98.49%
    2,2′-Dihydroxy-6,6′-dinaphthyl disulfide (PIR-3.5) is a PAK1 inhibitor.
    2,2′-Dihydroxy-6,6′-dinaphthyl disulfide
  • HY-178812
    PI3Kα-IN-27
    Inhibitor
    PI3Kα-IN-27 (Compound 50b) is an orally active PI3K-α inhibitor, with an IC50 of 40 nM. PI3Kα-IN-27 effectively inhibits PAK3, p110α, phospho-mTOR and phospho-ERK1/2. PI3Kα-IN-27 induces early Apoptosis. PI3Kα-IN-27 shows anticancer activity against pancreatic cancer, lung cancer, breast cancer.
    PI3Kα-IN-27
  • HY-P10106
    TAT-PAK18 inhibitory peptide
    Inhibitor
    TAT-PAK18 inhibitory peptide is a membrane-permeable PAK inhibitory peptide. TAT-PAK18 inhibitory peptide reduces F-actin clusters and occludes the effect of Shank3 knockdown.
    TAT-PAK18 inhibitory peptide
  • HY-RS09996
    PAK5 Human Pre-designed siRNA Set A
    Inhibitor

    PAK5 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PAK5 Human Pre-designed siRNA Set A
  • HY-174822
    PAK4-IN-6
    Degrader
    PAK4-IN-6 is a selective degrader of PAK4. PAK4-IN-6 can be used to synthesize PROTACs such as CPS-021 (HY-174247).
    PAK4-IN-6
  • HY-RS09994
    Pak4 Mouse Pre-designed siRNA Set A
    Inhibitor

    Pak4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pak4 Mouse Pre-designed siRNA Set A
  • HY-119216
    AZ13711265
    Inhibitor
    AZ13711265 is an orally active PAK1 inhibitor with high selectivity. AZ13711265 has IC50 values of 0.58 nM and 0.11 µM for PAK1 and pPAK1, respectively. AZ13711265 has low lipophilicity and low clearance, and can be used as an in vivo probe compound for PAK1. AZ13711265 can be used in the study of cancer.
    AZ13711265
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.